This critical gap motivates our comprehensive review to synthesize the mechanistic rationale for AKT targeting across gynecologic cancers, overcome therapeutic resistance, and provide a roadmap for biomarker-driven clinical development - addressing an urgent unmet need in female-specific cancers. Here, AKT1 is linked to female reproductive organ cancer.